Engineered T cell-derived extracellular vesicles for cancer immunotherapy
BME Horizon · 2024
DOI: 10.70401/bmeh.2026.0017 ↗Kurz gefasst
Fachartikel in der Zeitschrift BME Horizon, 2024. Verfasst von Rui Diao und 2 weiteren Autor:innen.
Abstract (Originalsprache)
T cell-derived extracellular vesicles (TcEVs) are nanoscale lipid bilayer-bound particles, including exosomes, microvesicles, apoptotic bodies, and T cell microvilli particles. TcEVs possess advantages such as high yield, favorable biocompatibility, low immunogenicity, and excellent solid tumor penetration, showing great potential in cancer immunotherapy. However, natural TcEVs exhibit weak targeting ability, limited immune activity, and low drug-loading capacity. To address these issues, several engineering strategies have been adopted to modify the vesicles through genetic engineering, surface modification, and drug-loading, thereby achieving effective treatment of both hematological and solid tumors. This review summarizes TcEVs’ classification, biological functions, engineering strategies, and applications in cancer immunotherapy, while discussing challenges and prospects to facilitate their clinical translation.
Zitieren
APA
Diao, R., Zhang, X., & Zhang, X. (2024). Engineered T cell-derived extracellular vesicles for cancer immunotherapy. BME Horizon. https://doi.org/10.70401/bmeh.2026.0017
Vancouver
Diao R, Zhang X, Zhang X. Engineered T cell-derived extracellular vesicles for cancer immunotherapy. BME Horizon. 2024. doi:10.70401/bmeh.2026.0017
BibTeX
@article{Diao2024,
author = {Diao, Rui and Zhang, Xiaozhou and Zhang, Xudong},
title = {Engineered T cell-derived extracellular vesicles for cancer immunotherapy},
journal = {BME Horizon},
year = {2024},
doi = {10.70401/bmeh.2026.0017}
}
EUVIMED